XML 54 R45.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue Recognition - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Sep. 30, 2023
Jun. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Disaggregation Of Revenue [Line Items]            
Payment period from distributors received from date of sale         45 days  
Net loss per share-basic [1] $ (0.06)   $ (0.05)   $ (0.08) $ (0.13)
Net loss per share-diluted [1] $ (0.06)   $ (0.05)   $ (0.08) $ (0.13)
Effect of significant financing component when transfer and customer payment of good or service occurs within one year or less         true  
Medicaid rebate            
Disaggregation Of Revenue [Line Items]            
Change in estimate recognized     $ 6.5     $ 15.1
Change in net income loss     $ 6.5     $ 15.1
Net loss per share-basic     $ (0.06)     $ (0.17)
Net loss per share-diluted     $ (0.06)     (0.17)
Exclusion of licensing revenue change in estimate            
Disaggregation Of Revenue [Line Items]            
Net loss per share-basic         $ (0.09) (0.16)
Net loss per share-diluted         $ (0.09) $ (0.16)
VASCEPA 1-Gram            
Disaggregation Of Revenue [Line Items]            
Product expiration date after being converted into capsule form         4 years  
VASCEPA 0.5-Gram            
Disaggregation Of Revenue [Line Items]            
Product expiration date after being converted into capsule form         3 years  
Edding            
Disaggregation Of Revenue [Line Items]            
Adjusted measure of performance and additional license revenue recognized   $ 4.0   $ 5.0    
HLS            
Disaggregation Of Revenue [Line Items]            
Adjusted measure of performance and additional license revenue recognized       $ 5.3    
Minimum            
Disaggregation Of Revenue [Line Items]            
Sales discount percentage 2.00%       2.00%  
Maximum            
Disaggregation Of Revenue [Line Items]            
Sales discount percentage 3.00%       3.00%  
[1] Excluding the licensing revenue change in estimates and Medicaid change in estimate, both discussed in Note 7 – Revenue Recognition, net loss per share, basic and diluted, for the three months ended September 30, 2023 would have been $(0.06) and net loss per share for the nine months ended September 30, 2024 and 2023 would have been $(0.09) and $(0.19), respectively.